Compare ARK Genomic Revolution ETF (ARKG) vs Vanguard Intermediate Term Corporate Bond ETF (VCIT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ARK Genomic Revolution ETF vs Vanguard Intermediate Term Corporate Bond ETF — how do they compare? ARK Genomic Revolution ETF trades at $40.45, while Vanguard Intermediate Term Corporate Bond ETF trades at $81.43. The key difference: ARK Genomic Revolution ETF is trading nearer its 52-week high, Vanguard Intermediate Term Corporate Bond ETF nearer its low. Which is the better fit depends on your goals.
| ARKG | VCIT | |
|---|---|---|
Sector | Sector/Thematic | Fixed Income |
52-Week High | $43.57 | $84.82 |
52-Week Low | $23.09 | $81.54 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARKG trades at $41.32, down 3.91% today, with a bullish technical signal driven by moving averages. Recent news highlights biotech ETF strength in June 2026, fueled by strong earnings, M&A activity, and AI-driven drug discovery optimism. Key support lies at $40, with resistance at $44.
The outlook remains positive given sector tailwinds, but risks include regulatory hurdles and market volatility. Investor sentiment is buoyed by industry growth catalysts, though selective investment approaches are noted by analysts.
VCIT, the Vanguard Intermediate-Term Corporate Bond ETF, trades at $81.81, down 0.13% with a bearish technical signal. The fund maintains a low 0.03% expense ratio and offers monthly dividend distributions, with recent payouts around $0.33-$0.34. Technical indicators show oversold conditions with RSI at 19.28, while moving averages signal bearish momentum. The fund provides exposure to over 2,000 investment-grade corporate bonds with a current SEC yield around 5.17%.
VCIT offers income-focused investors a balanced approach to intermediate-term corporate bonds with competitive yields and low costs. Key risks include interest rate sensitivity and corporate credit quality concerns. The fund's diversification across investment-grade issuers provides stability, though economic uncertainty could impact bond valuations. Current technical weakness may present entry opportunities for yield-seeking investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ARK Genomic Revolution ETF
ARKG is an actively managed ETF that invests in the genomic revolution. It focuses on companies leading in gene editing, CRISPR technology, therapeutics, and molecular diagnostics, including firms like CRISPR Therapeutics and Tempus AI.
Read more on ARKG →About Vanguard Intermediate Term Corporate Bond ETF
VCIT tracks the Bloomberg U.S. 5-10 Year Corporate Bond Index, providing exposure to investment-grade debt from industrial, utility, and financial companies. It acts as a middle-ground bond fund, offering higher yields than short-term bonds with less price volatility than long-term corporate debt.
Read more on VCIT →
